Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.
3.

Progesterone metabolites in breast cancer.

Wiebe JP.

Endocr Relat Cancer. 2006 Sep;13(3):717-38. Review.

4.
7.

The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics.

Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ, Zhang G.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):201-8. Epub 2005 Feb 19.

PMID:
15860263
8.

Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphaP) and 3alpha-dihydroprogesterone (3alphaHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines.

Wiebe JP, Beausoleil M, Zhang G, Cialacu V.

J Steroid Biochem Mol Biol. 2010 Jan;118(1-2):125-32. doi: 10.1016/j.jsbmb.2009.11.005. Epub 2009 Nov 17.

PMID:
19931389
9.

Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride.

Wiebe JP, Rivas MA, Mercogliano MF, Elizalde PV, Schillaci R.

J Steroid Biochem Mol Biol. 2015 May;149:27-34. doi: 10.1016/j.jsbmb.2015.01.004. Epub 2015 Jan 13.

PMID:
25595041
11.

Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites.

Pawlak KJ, Wiebe JP.

J Steroid Biochem Mol Biol. 2007 Nov-Dec;107(3-5):172-9. Epub 2007 Jun 22.

PMID:
17683929
12.

Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines.

Sinreih M, Anko M, Zukunft S, Adamski J, Rižner TL.

Chem Biol Interact. 2015 Jun 5;234:297-308. doi: 10.1016/j.cbi.2014.11.012. Epub 2014 Nov 23.

PMID:
25463305
13.
14.

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Tindall DJ, Rittmaster RS.

J Urol. 2008 Apr;179(4):1235-42. doi: 10.1016/j.juro.2007.11.033. Epub 2008 Feb 20. Review. Erratum in: J Urol. 2008 Jun;179(6):2490.

15.

5α-reductase type 3 enzyme in benign and malignant prostate.

Titus MA, Li Y, Kozyreva OG, Maher V, Godoy A, Smith GJ, Mohler JL.

Prostate. 2014 Feb;74(3):235-49. doi: 10.1002/pros.22745. Epub 2013 Oct 22.

16.

Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.

Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, Russell DW, Schweikert HU.

J Clin Endocrinol Metab. 2002 Dec;87(12):5401-7.

PMID:
12466325
17.

Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.

Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HA.

Breast Cancer Res. 2013 May 11;15(3):R38. doi: 10.1186/bcr3422.

18.

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S.

JAMA. 2012 Mar 7;307(9):931-9. doi: 10.1001/jama.2012.227.

PMID:
22396515
19.

Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).

Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K, Palackal N.

Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49.

PMID:
11165022
20.

Error occurred: cannot get document summary

PMID:
23663549

Supplemental Content

Support Center